Appendix
← Clinical Reader
Dermatology/Ophthalmology

Malignant Eyelid Lesions

Malignant eyelid lesions are a unique subset of cancers that range from some of the most common forms of cutaneous malignancy, such as basal cell and squamous cell carcinoma, to much rarer forms of metastatic disease. Many cases may resemble or arise from benign or premalignant lesions, necessitating a thorough history, careful examination, and prompt biopsy to ensure optimal patient outcomes. This course discussion focuses on the broad concepts of eyelid malignancy, including etiology, epidemio

v1 · Reviewed Nov 7, 2026 by Automated Clinical Reviewer (Strict Verbatim v1)
  • necessitating a thorough history, careful examination, and prompt biopsy to ensure optimal patient outcomes.
  • Clinicians should evaluate lesion duration, growth rate, tenderness, discharge, bleeding, ulceration, lash loss, and recurrence.
  • Risk factors such as excessive ultraviolet exposure, prior skin cancer, immunosuppression, and nonhealing cutaneous lesions should increase suspicion for malignancy.
  • When malignancy is suspected, prompt referral for biopsy and histopathologic evaluation is warranted.
  • Any periorbital skin malignancy, if neglected, can invade the orbit, resulting in significant morbidity to achieve control of the disease.
  • A detailed history and a thorough examination are essential when assessing a suspicious eyelid lesion.
  • Careful examination under magnification with slit-lamp biomicroscopy or dermoscopy improves lesion characterization and may reduce unnecessary surgical procedures while facilitating earlier diagnosis and treatment.
  • Histopathologic examination remains the gold standard for the diagnosis of malignant lesions and is required before definitive treatment.
  • Full-thickness or excisional biopsies are preferred for certain malignant lesions (eg, melanoma), as depth of invasion is a critical prognostic factor.
  • comprehensive care should include a dermatology referral for a full-body skin examination, as patients diagnosed with a single malignant lesion are at increased risk of additional cutaneous malignancies, for which annual surveillance is strongly recommended.
  • when a patient's presentation raises concern for more extensive disease (eg, bony invasion or metastasis), further diagnostic imaging should be pursued for both prognostic assessment and surgical planning.
  • A 2024 systematic review of SCC found that computed tomography (CT) imaging altered management in nearly one-third of high-risk patients and demonstrated excellent sensitivity and specificity (96.4% and 100%, respectively) for detecting nodal metastasis.
  • Clinicians should assess for lesions with irregular pigmentation, ulceration with crusting or bleeding, telangiectatic vessels, or loss of eyelashes or cutaneous rhytids.
  • Eversion of the lower lid and double-eversion of the upper lid are vital to ascertain the involvement of the conjunctival and fornices.
  • The preauricular, postauricular, submandibular, and submental lymph nodes should be assessed for lymphadenopathy.
  • best-corrected visual acuity, color vision, extraocular motility, pupillary responses, and visual field should also be measured.
  • Ultrasonography or CT scans of the nodal basins may be used.
  • Enlarged lymph nodes should be biopsied.
  • Sentinel node biopsy can be considered for periocular sebaceous carcinoma.
  • Evaluation of distant metastasis with a CT or positron emission tomography scan should be used for confirmed nodal metastasis.
AJCC Staging System
The 8th edition of the American Joint Committee on Cancer staging system for eyelid carcinoma may be used.
Clark's Level of Invasion
Clark's level of invasion
Breslow Tumor Thickness
Breslow tumor thickness
Mayo Muir-Torre Syndrome Risk Score
Genetic testing for Muir-Torre syndrome is recommended if the Mayo Muir-Torre syndrome risk score is≥ 2.
  • The primary treatment modality for BCC of the eyelid remains surgical excision, typically Mohs micrographic surgery or local excision with 3 to 4 mm surgical margins.
  • If SCC is confirmed on pathology, treatment is primarily surgical excision.
  • Mohs micrographic surgery or complete circumferential peripheral and deep margin assessment should be the primary management for periocular sebaceous carcinoma.
  • Primary treatment of local malignancy consists of local, wide skin excision.
  • For surgical excision, a wide excision with 5 mm margins is recommended.
Not specified in source
Not specified in source
Adult
3 to 4 mm surgical margins
Renal
Not specified in source
Duration
Not specified in source
Not specified in source
Not specified in source
Adult
5 mm margins
Renal
Not specified in source
Duration
Not specified in source
  • More recent studies have shown the use of neoadjuvant vismodegib before surgical excision to avoid disfiguring orbital exenteration.
  • Though the trial was not specific to eyelid tumors, it found that surgery was superior to imiquimod.
  • These findings suggest a possible role for imiquimod in selected cases of eyelid BCC.
  • If confirmed as a keratoacanthoma, ophthalmologists may choose to monitor or excise the lesion, depending on its size and location.
  • If the SCC shows perineural invasion into the orbit, the patient should be considered for neoadjuvant treatment, globe-sparing or total orbital exenteration (depending on the extent of spread), and sentinel lymph node biopsy.
  • Although surgical excision remains the standard of care for SCC, it is not always clinically possible; in such cases, radiation remains a viable option.
  • Thus, agents such as cetuximab, erlotinib, and gefitinib, which target and inhibit the epidermal growth factor receptor, have shown promise in SCC treatment, mainly to stabilize disease when surgical management is not possible.
  • Topical imiquimod, a topical immunomodulatory agent of the imidazoquinoline family, functions by activation of the innate and adaptive/acquired immune systems.
  • In 2010, Ross et al were the first to successfully use imiquimod to treat moderately differentiated SCC of the eyelid.
  • Positive surgical margins may be treated with adjuvant double freeze-thaw cryotherapy or topical mitomycin.
  • If Mohs micrographic surgery or complete circumferential peripheral and deep margin assessment is not feasible, staged wide local excision can be performed; however, this may increase morbidity.
  • Extensive orbital involvement may be treated with orbital exenteration or radiotherapy as a monotherapy.
  • Adjuvant radiotherapy may be considered in sebaceous carcinoma with perineural invasion.
  • Sentinel lymph node biopsy (SLNB) may aid in the treatment of patients with eyelid melanoma.
  • For patients presenting with metastatic disease, surgical excision is not curative.
  • Dacarbazine, an imidazole carboxamide chemotherapeutic agent, has been the first drug therapy for metastatic melanoma since 2006.
  • Biologic immunotherapies (eg, interleukin-2 and interferons), vaccination strategies, and adoptive cell therapy are all immunotherapies that have been employed to combat metastatic malignant melanoma.
  • Most notably, immune checkpoint inhibitors (ie, ipilimumab, nivolumab, and pembrolizumab) are the newest and fastest-growing area of investigation in treating metastatic melanoma.
  • Chemotherapy is effective in treating MCC as a first-line treatment for disseminated or metastatic disease rather than as a local or adjuvant treatment.
  • Immune checkpoint inhibitors such as pembrolizumab, nivolumab, and avelumab are currently being added to the treatment portfolio of MCC.
  • Notably, avelumab has demonstrated efficacy in treating eyelid-specific diseases.
  • Surveillance is recommended every 6 months for the first 3 years after treatment, then annually.
  • Periodic lymph node basin ultrasonography may be considered.
  • Misdiagnosis may result in prolonged observation, leading to more extensive local growth of the lesion.
  • Iatrogenic complications from periocular surgery and radiotherapy carry several risks, including those listed below.
  • Lagophthalmos
  • Symblepharon
  • Eyelid retraction
  • Ptosis
  • Ectropion
  • Entropion
  • Trichiasis
  • Dry eye syndrome from exposure, aqueous deficiency, or evaporation
  • Damage to the nasolacrimal system
  • Diplopia
  • Globe injury and damage to surrounding structures
  • Orbital hemorrhage
  • Infection
  • Poor tissue healing (primarily with radiotherapy)
  • Poor cosmetic outcome
  • Psychologic distress
  • Each immunologic and chemotherapeutic agent carries specific complications, and clinicians should work closely with oncologists and pharmacists when considering treatment options.
  • The 2 most important modifiable risk factors include sun protection and tobacco avoidance or cessation.
  • Patients should avoid UV radiation; short-wavelength UVB is more damaging than long-wavelength UVA radiation and can induce DNA damage in tumor-suppression genes.
  • Studies suggest that UV exposure contributes to almost 65% of melanoma and 90% of nonmelanoma skin cancer.
  • In a recent retrospective review of eyelid malignancies by the American Academy of Ophthalmology, smoking was found to have a clear positive association with the majority of cancers studied, with the odds ratio reaching nearly 1.6 for SCC.
  • review
    Malignant Eyelid Lesions. StatPearls [Internet] — Harkaran Rana, Thomas J. Stokkermans, Boonkit Purt, Matthew Miller, Eva Chou — StatPearls Publishing, 2026

Decision support only. Verify against local protocols and current labeling. Source: www.ncbi.nlm.nih.gov